Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ALPS Clear all
Recruiting No phase listed Observational

Clinical Outcomes of the ALPS Proximal Humerus Plating System

NCT03328650
View directory record Official record
Conditions
Proximal Humeral Fracture
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 22, 2026, 9:02 AM EDT
Active, not recruiting Phase 2 Interventional

Immune Disorder HSCT Protocol

NCT01821781
View directory record Official record
Conditions
Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Hyper-IgM, DiGeorge Syndrome, Chediak-Higashi Syndrome, Common Variable Immune Deficiency, Immune Dysregulatory Disorders, Hemophagocytic Lymphohistiocytosis, IPEX, Autoimmune Lymphoproliferative Syndrome, X-linked Lymphoproliferative Syndrome
Interventions
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 22, 2026, 9:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study

NCT03076775
View directory record Official record
Conditions
Pregnancy Preterm, Neonatal Hypoglycemia, Hyperglycemia Drug Induced
Interventions
Maternal glycemic control
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jul 22, 2026, 9:02 AM EDT
Completed Phase 1 Interventional

Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome

NCT00013689
View directory record Official record
Conditions
Autoimmune Disease, Lymphoproliferative Disorder
Interventions
Fansidar (pyrimethamine and sulfadoxine)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 9:02 AM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 22, 2026, 9:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus for Autoimmune Disease of Blood Cells

NCT00392951
View directory record Official record
Conditions
Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune, Autoimmune Neutropenia, Lupus Erythematosus, Systemic, Inflammatory Bowel Disease, Rheumatoid Arthritis
Interventions
sirolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jul 22, 2026, 9:02 AM EDT
Recruiting Phase 2 Interventional

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

NCT06730126
View directory record Official record
Conditions
Autoimmune Lymphoproliferative Syndrome
Interventions
Soquelitinib
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 9:02 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparative Autoantibody and Immunologic Cell Marker Study

NCT02422875
View directory record Official record
Conditions
Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jul 22, 2026, 9:02 AM EDT
Completed Phase 1 Interventional

Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome

NCT00065390
View directory record Official record
Conditions
Autoimmune Disease, Lymphatic Disease, Lymphoproliferative Disorder
Interventions
Pyrimethamine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 9:02 AM EDT
Recruiting No phase listed Observational

Study of Autoimmune Lymphoproliferative Syndrome (ALPS)

NCT00001350
View directory record Official record
Conditions
Benign Lymphoproliferative Disorder
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 99 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 9:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)

NCT00605657
View directory record Official record
Conditions
ALPS, Hypersplenism, Lymphadenopathy
Interventions
Valproic Acid, CT Scan, Blood Sample
Drug · Procedure
Lead sponsor
Koneti Rao
NIH
Eligibility
2 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Jul 22, 2026, 9:02 AM EDT
Recruiting No phase listed Observational

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

NCT04528355
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Interventions
data collection
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 22, 2026, 9:02 AM EDT
Not listed Not applicable Interventional

The Impact of Robot Assisted Therapy and Metacognitive Skills Training for Children With Hemiparesis

NCT04309266
View directory record Official record
Conditions
Hemiparesis, Hemiplegic Cerebral Palsy, Hemiparesis;Poststroke/CVA
Interventions
Amadeo by Tyromotion, Active Learning Protocol for Stroke
Device · Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Jul 22, 2026, 9:02 AM EDT
Completed No phase listed Observational

Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma

NCT00068146
View directory record Official record
Conditions
Lymphoproliferative Disorders, Lymphoma
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 22, 2026, 9:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

NCT01222247
View directory record Official record
Conditions
Pregnancy, Respiratory Distress Syndrome, Pregnancy Outcomes, Preterm Birth
Interventions
Betamethasone, Placebo
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
2,831 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2022
U.S. locations
17
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Jul 22, 2026, 9:02 AM EDT